Fighting COVID19 with calpain inhibitors / Consortium: Calpain-antivirals

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $491,216.3
  • Funder

    Academy of Finland
  • Principal Investigator

    Varpu Marjomäki
  • Research Location

    Finland
  • Lead Research Institution

    University of Jyväskylä
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

It is important to develop coronavirus (CoV) targeting antivirals as it remains unclear if and when a safe and efficient vaccine becomes available. We propose to create antivirals against CoV proteases that process the virus polyprotein to virus capsid proteins by using a novel approach, by inhibiting cellular calpain enzymes. We have preliminary results showing that calpain inhibitors prevent COVID19 infection. In addition, we have shown that calpain inhibitors knock down both host cell calpains and the enteroviral protease, that both contribute to virus polyprotein processing. We reckon that calpain inhibitors attack both host cell calpain proteases and viral 3C-like protease, closely resembling enterovirus 3C protease, and both process the viral polyprotein. In the project we will find the inhibitor with best efficacy, chemically optimize the inhibitor with new design, synthesis and efficacy against virus infection.